#naturemedicine
These are public posts tagged with #naturemedicine. You can interact with them if you have an account anywhere in the fediverse.
Whoa
A new study shows that #microplastics are making their way into human #brains —w/potentially dangerous effects on people’s #health & mental #acuity.
A paper published Mon in #NatureMedicine found that the tiny fragments of #plastic are passing the blood-brain barrier & into human brains, & the amount of #microplastics in the #brain appears to be increasing over time. There were 50% more fragments in brains analyzed in 2024 than in 2016.
#science #medicine #climate
https://www.washingtonpost.com/climate-environment/2025/02/03/microplastics-human-brain-increase/
@iuculano@masto.aiVia #ANSA @ 11:11am ET on Jan 27, 2025
Extreme heat caused by the #ClimateCrisis risks causing over 2.3 million deaths in #Europe's cities by the end of the century, according to a study by the London School of Hygiene & Tropical Medicine, published #NatureMedicine, and #Italian cities are among those set to be hit hardest.
Extreme heat caused by the climate crisis risks causing…
Agenzia ANSAA Personalized Brain Pacemaker for Parkinson’s - In a new frontier for deep brain stimulation, researchers used A.I. to develop individual... - https://www.nytimes.com/2024/08/19/health/parkinsons-brain-pacemaker.html #universityofcaliforniasanfrancisco #naturemedicine(journal) #artificialintelligence #parkinsonsdisease #research #brain
In a new frontier for deep brain stimulation, researchers…
The New York Times"The Food and Drug Administration on Friday approved the first pill for postpartum depression, a milestone considered likely to increase recognition and treatment of a debilitating condition that afflicts about a half-million women in the United States every year."
https://www.nytimes.com/2023/08/04/health/postpartum-depression-pill-fda.html?action=click&module=Well&pgtype=Homepage§ion=Health
In April I wrote about how this new class of drugs were developed for #NatureMedicine. Read it at the link below:
Gene therapy with AAV vectored micro-dystrophin for Duchenne muscular dystrophy. My latest #ClinicalPipeline column for #NatureMedicine.
I wrote about RSV vaccines in my #NatureMedicine column in February.
Very good news this week with the FDA approval of GSK's RSV vaccine for adults 60 and over - it's the first approved RSV vaccine.
https://edition.cnn.com/2023/05/03/health/first-rsv-vaccine-approved/index.html
Several other candidate RSV vaccines are at a late stage of development, including mRNA based vaccines. The next big thing to watch for are those seeking to protect newborns and infants by maternal immunisation.
#RSV #Vaccine #RespiratoryVirus #drugdevelopment #Pharma #Immunology
The FDA has approved Biogen's ALS drug, Tofersen, an antisense oligo targeting SOD1. I wrote about this back in September in my Clinical Pipeline column as part of a shift towards approving drugs based on biomarkers without clear signs of clinical efficacy*.
https://www.nature.com/articles/d41591-022-00098-w
*You can have a look at the trial data in NEJM, in a study that concluded that "In persons with SOD1 ALS, tofersen reduced concentrations of SOD1 in CSF and of neurofilament light chains in plasma over 28 weeks but did not improve clinical end points and was associated with adverse events."
#NatureMedicine #amyotrophiclateralsclerosis #drugdevelopment #pharma
My latest Clinical Pipeline column for #NatureMedicine, on fitusiran, a small interfering RNA for the treatment of hemophilia A or B. It may be particularly useful for patients with inhibitors (antibodies against clotting factors).
#drugdevelopment #drugdiscovery #SciComm #sciencecommunication #pharma #hemophilia 
"On 2 February 2022, President Joe Biden announced new efforts to extend the Cancer Moonshot1 to address bold but achievable new goals: to reduce cancer mortality by at least 50% in the next 25 years and improve the experience of people and their families living with and surviving cancer."
The topic of my latest #NatureMedicine Clinical Pipeline column, zuranolone, represents an improvement in both safety & ease of administration over its on its predecessor, brexanolone (which was the first drug approved specifically for postpartum depression in 2019). The case for it in major depressive disorder is more complex.
My latest Clinical Pipeline column for #NatureMedicine is a look at zuranolone, a new antidepressant developed by Sage & Biogen, targeting the GABA pathway.
#drugdiscovery #drugdevelopment #depression #GABA #neuroscience
My latest Clinical Pipeline column for #NatureMedicine is now online. A new take on heart failure using iPSC derived cardiomyocytes.
'Using two independent real-world datasets from three different countries and an independent validation cohort based on the global, double-blind, placebo-controlled, phase 3 RECOURSE trial, we demonstrate that codon-specific KRAS mutations predict OS benefit for patients treated with the chemotherapeutic agent FTD/TPI in late-stage mCRC.'
Interesting piece in Nature about the type 1 #diabetes drug Teplizumab, the first that the FDA has ever approved to delay the onset of the disease:
I wrote about the drug in mid December for #NatureMedicine
#HIV patient #cured after bone marrow transplant in rare case
A man in Germany who had been diagnosed w/HIV has been declared free of the virus after receiving HIV-resistant stem cells through a bone marrow transplant intended to treat leukemia. Acc/to research published in the journal #NatureMedicine on Mon, the man was monitored for >9 yrs after the 2013 transplant, & there is now “strong evidence” that he has been cured.
https://www.washingtonpost.com/health/2023/02/21/duesseldorf-patient-hiv-cured-stem-cell/
There is “strong evidence” that the man in Düsseldorf,…
www.washingtonpost.comMy latest Clinical Pipeline column for #NatureMedicine is out, a look at Moderna's RNA vaccine for RSV & a survey of what's, well, in the pipeline, for RSV immunotherapies, including vaccines and monoclonals.
#Vaccine #drugdiscovery #drugdevelopment #mRNA #RSV #immunology #MonoclonalAntibody
My latest Clinical Pipeline column for #NatureMedicine is out today, a look at Moderna's RNA vaccine for RSV & a survey of what's, well, in the pipeline, for RSV immunotherapies, including vaccines and monoclonals.
#Vaccine #drugdiscovery #drugdevelopment #mRNA #RSV #immunology #MonoclonalAntibody
Sagy et al. have recently published in #NatureMedicine an analysis of the real-world efficacy of #JYNNEOS, the #smallpox shot redeployed against #monkeypox.
https://www.nature.com/articles/s41591-023-02229-3
Last Fall I wrote a column for Nature Medicine that touched on the FDA's Animal Rule, used in the approval of anti-smallpox drugs due to the difficulty in designing ethically acceptable efficacy screens.
"Despite the growing number of regulatory approvals for use of these drugs in a number of different malignancies, it is now becoming clear that many patients who receive ICIs do not benefit from treatment but remain at risk for potentially serious immune-related adverse events. Expanding the benefit of ICIs to more patients and limiting the impact of their adverse effects will require better biomarkers of response and toxicity."
Off-the-shelf CARTs
"Nevertheless, generation of autologous CAR T cell products is extremely time consuming and costly, prompting researchers to explore alternative strategies to overcome these limitations. In this issue of Nature Medicine, Mailankody et al.4 report results of part A of the phase 1 UNIVERSAL clinical trial, which evaluated ALLO-715, an allogeneic off-the-shelf anti-BCMA CAR T cell product."
#CARTcells #Immunology #Immunotherapy #NatureMedicine #MultipleMyeloma #Hematology
